LMNA and cardiomyopathy: Rapamycin-mediated mTORC1 inhibition rescues cardiac, skeletal muscle and adipose function and robustly enhances survival in Lmna−/− mice [15, 16], a model for the cardiomyopathy and muscular dystrophy associated with human mutations in LMNA [8].